Ethanol increases the expression of functional delta-opioid receptors in neuroblastoma x glioma NG108-15 hybrid cells.
Ethanol inhibits opioid peptide binding to the delta-opioid receptor. When neuroblastoma x glioma NG108-15 hybrid cells are grown with 25-200 mM ethanol, opioid receptor density increases up to 2-fold without a change in receptor affinity. Since changes in neurotransmitter receptor density may be important in neuronal adaptations to ethanol, we investigated the underlying mechanisms and functional consequences of this phenomenon. The opiate antagonist, naloxone, also increased opioid receptor number, but produced a smaller effect than ethanol with greater fractional inhibition of binding; long term enhancement of binding by ethanol is therefore not a simple function of acute receptor inhibition. Ethanol did not inhibit receptor down-regulation by etorphine, an opiate agonist, and therefore is not likely to increase receptor expression through interference with tonic down-regulation by endogenous opioid peptides. Ethanol increased opioid receptor expression in NG108-15 cells treated with actinomycin D, but not cycloheximide; hence, normal protein synthesis, but not DNA transcription, may be required for this response. The opioid receptors induced in ethanol-treated cells were subject to normal up-regulation by naloxone, down-regulation by etorphine, and acute inhibition of agonist binding by Na+. Etorphine maximally inhibits cyclic AMP accumulation in NG108-15 cells with only fractional occupancy of opioid receptors. Chronic ethanol exposure increased the receptor reserve for this response, resulting in a 3.5-fold increase in the potency of etorphine for inhibiting phenylisopropyladenosine-stimulated cyclic AMP accumulation. Neuronal adaptation to ethanol may involve changes in the density of receptors that regulate cellular levels of cyclic AMP.
D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D004247:DNA / Q000378:metabolism; D003609:Dactinomycin / Q000494:pharmacology; D004174:Diprenorphine / Q000378:metabolism; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives / Q000378:metabolism; D016308:Enkephalin, Leucine-2-Alanine; D000431:Ethanol / Q000494:pharmacology*; D005048:Etorphine / Q000378:metabolism; D005910:Glioma; D006825:Hybridomas / Q000378:metabolism*; D009270:Naloxone / Q000494:pharmacology; D009447:Neuroblastoma; D010660:Phenylisopropyladenosine / Q000494:pharmacology; D011957:Receptors, Opioid / Q000096:biosynthesis*; D017465:Receptors, Opioid, delta; D012964:Sodium / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects
D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D003609:Dactinomycin; D004174:Diprenorphine; D010660:Phenylisopropyladenosine; D009270:Naloxone; D000431:Ethanol; D005048:Etorphine; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; D004247:DNA; D003513:Cycloheximide; D012964:Sodium; D000242:Cyclic AMP